Nutrition Intervention in AIDS Wasting

National Institutes of Health (NIH)

Status and phase: Completed; Phase 4

Conditions: HIV Wasting Syndrome

Treatments: Drug: oxandrolone; Behavioral: Progressive Resistance Training

Study type: Interventional

Funder types: NIH

Identifiers

NCT00006167

NIAW (completed)

DK51011

Details and patient eligibility

About

There are no guidelines for appropriate nutritional management of weight loss or wasting in HIV infection. Some treatments may increase weight, but without improving muscle mass or quality of life. In this clinical trial AIDS patients with wasting are randomized to one of three nutritional strategies and studied over a 12-week period: 1) optimal oral nutrition with counseling and protein and calorie supplementation, and a placebo pill; 2) optimal oral nutrition with the oral androgen, oxandrolone at 20 mg daily; and 3) optimal oral nutrition with progressive resistance training (PRT). In all participants, dietary intervention is maximized by weekly personalized counseling to address individual issues and concerns. Two primary outcomes are assessed: thigh muscle mass and quality of life. Our findings can be used to develop guidelines for standards of nutritional care among AIDS patient with the wasting syndrome.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Loss of 10% of usual body weight, OR loss of 5% of usual body weight within the previous 6 months, OR BMI20kg/m2. If the candidate is taking a protease inhibitor, he/she must have not regained weight since initiating the medication over a period of at least 4 weeks prior to screening.
• Documented HIV-positive
• Able to eat
• English-speaking
• Compliance with medical regimens
• For heterosexually active women: willingness to use an effective means of birth control
• Patient and physician not planning to start new treatments for HIV infection or weight loss during the 12 weeks of study.

Exclusion criteria

• Vomiting 1 time/day or diarrhea 4 times/day on average in the previous week
• Fever 101 F within the previous week
• Receiving induction treatment for one of the following (new diagnosis or recurrence within 4 weeks):

Pneumocystis carinii pneumonia Cryptococcal meningitis Cytomegalovirus retinitis or pneumonitis Toxoplasmosis Mycobacterium avium complex Visceral Kaposi's Sarcoma Lymphoma Pulmonary tuberculosis

• Received corticosteroids, estrogens, progesterones, androgens, oral anticoagulants, or growth hormone within the previous three months
• History of life-threatening reaction to oxandrolone or testosterone
• Currently pregnant
• History of congestive heart failure, myocardial infarction, angina/coronary artery disease, uncontrolled hypertension, cerebrovascular accident, hepatic failure, bleeding disorder, diabetes, nephrotic syndrome, cancer of the breast or prostate, or hypercalcemia
• Milk product allergy
• Current use of injected drugs
• Participation in an exercise program or strength training within the previous 4 weeks
• Any medical condition which renders the participant physically incapable of performing strength exercises
• Serum total testosterone level at least 300ng/ml, unless patient and primary physician prepared to begin testosterone injections concurrent with study enrollment (men only).